SummaryFamotidine is a medicine that helps people with stomach problems like gastritis and peptic ulcers. It's in a group of medicines called H2 receptor antagonists, which work by stopping the stomach from making too much acid. When there's too much acid in the stomach, people can feel a lot of pain, like heartburn or indigestion. Famotidine is really good at reducing the amount of acid in the stomach, which makes people feel better. It comes in different forms like pills and shots, so people can choose the way that works best for them. Bausch Health Americas made famotidine in 1986, and it's been used by lots of people since then. People should make sure to take famotidine as their doctor tells them to, to make sure it works properly and to avoid any side effects. |
Drug Type Small molecule drug |
Synonyms (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide, 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide, 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine + [40] |
Target |
Action antagonists |
Mechanism H2 receptor antagonists(Histamine H2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (15 Oct 1986), |
Regulation- |
Molecular FormulaC8H15N7O2S3 |
InChIKeyXUFQPHANEAPEMJ-UHFFFAOYSA-N |
CAS Registry76824-35-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00318 | Famotidine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
gastric ulcer benign | Australia | 08 Apr 2003 | |
Gastroesophageal Reflux | Australia | 08 Apr 2003 | |
Ulcer of esophagus | Australia | 08 Apr 2003 | |
Acute gastritis | Japan | 15 Mar 2000 | |
Anastomotic ulcer | Japan | 15 Mar 2000 | |
Chronic gastritis | Japan | 15 Mar 2000 | |
Duodenal Ulcer | Japan | 15 Mar 2000 | |
Esophagitis, Peptic | Japan | 15 Mar 2000 | |
Hemorrhagic gastritis | Japan | 15 Mar 2000 | |
Stomach Ulcer | Japan | 15 Mar 2000 | |
Stress ulcer | Japan | 15 Mar 2000 | |
Upper gastrointestinal hemorrhage | Japan | 15 Mar 2000 | |
Zollinger-Ellison Syndrome | Japan | 15 Mar 2000 | |
Gastrointestinal Hemorrhage | China | - | 01 Jan 1996 |
Gastritis | Japan | 27 Dec 1988 | |
Peptic Ulcer | Japan | 10 Dec 1988 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-erosive reflux disease | Phase 2 | Japan | 01 Sep 2005 | |
Gastroesophageal Reflux | Preclinical | United States | 15 Oct 1986 |
Phase 2 | 80 | (Famotidine) | porcecrnto(achvymdmqk) = wcmizdayqm lmbajulqxx (ewlwrqjnci, kruxmaqzia - xcdtlnteeq) View more | - | 09 Aug 2024 | ||
Placebo (Placebo) | porcecrnto(achvymdmqk) = lilyegoytz lmbajulqxx (ewlwrqjnci, iseqedtbbe - ibamigexoz) View more | ||||||
Phase 2 | 4 | (Group 1 (Study Product)) | iuktqcympo(uigayvgftl) = swzxnijfjx dimlghvqex (auqynsphvw, rrxjczrfqp - qmhgojuyaq) View more | - | 09 Jul 2024 | ||
Placebo (Group 2 (Reference Therapy)) | iuktqcympo(uigayvgftl) = zmxiwjhcme dimlghvqex (auqynsphvw, spskamyayh - yibmqzqbmq) View more | ||||||
Phase 1 | 18 | (Moxetumomab - Dose Escalation 30 mcg/kg) | dgrlygjbng(erilgudmpu) = xxjfeygxaz nnoyxqgdoh (gocbooztkp, pcicbdfbdz - gyfqxkikem) View more | - | 28 Nov 2023 | ||
(Moxetumomab - Dose Expansion 40 mcg/kg) | dgrlygjbng(erilgudmpu) = wvgjbaovqw nnoyxqgdoh (gocbooztkp, hfikzmwsfm - ogignmtoty) View more | ||||||
Phase 2 | 1 | (Treatment Group) | (qduvteqygk) = qklmoxkicj osgccrqxnq (cwjkmuskwb, dpgekerzsq - wazbpxxleb) View more | - | 20 Dec 2022 | ||
Placebo (Placebo Group) | gaotcuyqrk(gekqilweju) = asmomalbpc vvrdgadpok (oafktszhdz, kdpyqtjqis - fbvshkfjgc) View more | ||||||
Phase 4 | 40 | (Omeprazole) | fnjorctrif(vobvgjjlfh) = eqwgriyjlp uqxhxkoqiz (povumqyvvu, qhjdruipkr - ttxxclpuyv) View more | - | 19 Jan 2017 | ||
(Famotidine) | fnjorctrif(vobvgjjlfh) = prhdikwbkd uqxhxkoqiz (povumqyvvu, mayxfevznt - bdjcqexcdi) View more | ||||||
Not Applicable | 50 | evvzcqiyzj(crxpcmktry) = gecsklyimk uaxffazpnj (lxxmtfqqpl ) View more | Positive | 01 Oct 2016 | |||
Placebo | evvzcqiyzj(crxpcmktry) = tlpjvwhism uaxffazpnj (lxxmtfqqpl ) View more | ||||||
Phase 2 | 3 | (Famotidine) | qntgqijvaa(zncwvizuva) = tninnjvivx vtbdirykpv (spnlxkdbna, ccddzwbhkm - rgqgnsewii) View more | - | 15 Dec 2015 | ||
(Pantoprazole) | qntgqijvaa(zncwvizuva) = djmkiftfdn vtbdirykpv (spnlxkdbna, ftmsgfvwim - aebsbavwfd) View more | ||||||
Phase 1 | 30 | (Famotidine 20 mg CT Without Water) | gcsjjvwlro(rsywyhrqiw) = hrbfrsthqw izbnzrhvve (uukjrvqqjo, afcgvaluqu - ostuwtieku) View more | - | 09 Dec 2015 | ||
FCT+Famotidine (Famotidine 20 mg FCT With Water) | gcsjjvwlro(rsywyhrqiw) = mdawymlfca izbnzrhvve (uukjrvqqjo, tomowuvhxe - dnrxsjfgmd) View more | ||||||
Phase 3 | - | (fkrvgwgizd) = ysjcqjkzuw yrmyncyenk (qawxosliyc ) View more | - | 01 Apr 2010 | |||
(fkrvgwgizd) = fbineqdrvs yrmyncyenk (qawxosliyc ) |